• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有时他们会回来:新型和旧型脊髓性肌萎缩症成人在 nusinersen 时代。

Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen.

机构信息

The NEMO Center in Milan, Neurorehabilitation Unit, ASST Niguarda Hospital, University of Milan, Milan, Italy.

Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Eur J Neurol. 2021 Feb;28(2):602-608. doi: 10.1111/ene.14567. Epub 2020 Oct 31.

DOI:10.1111/ene.14567
PMID:33012052
Abstract

BACKGROUND AND PURPOSE

Following the commercial availability of nusinersen, there have been a number of new referrals of adults with spinal muscular atrophy (SMA) not regularly followed in tertiary-care centers or enrolled in any disease registry.

METHODS

We compared demographics and disease characteristics, including assessment of motor and respiratory function, in regularly followed patients and newcomers subdivided according to the SMA type.

RESULTS

The cohort included 166 adult patients (mean age: 37.09 years): one type I, 65 type II, 99 type III, and one type IV. Of these 166, there were 67 newcomers. There was no significant difference between newcomers and regularly followed patients in relation to age and disease duration. The Hammersmith Functional Motor Scale Expanded and Revised Upper Limb Module scores were higher in the regularly followed patients compared to newcomers in the whole cohort and in both SMA II and II. A difference was also found on ventilatory status (p = 0.013) and Cobb's angle >50° (p = 0.039) between the two subgroups. No difference was found in scoliosis surgery prevalence (p > 0.05).

CONCLUSIONS

Our results showed differences between the two subgroups, even if less marked in the type III patients. In the type II patients, there was a higher proportion of newcomers who were in the severe end of the spectrum. Of the newcomers, only approximately a third initiated treatment, as opposed to the 51% in the regularly followed patients. The identification of patients who were not part of the registries will help to redefine the overall prevalence of SMA and the occurrence of different phenotypes.

摘要

背景与目的

随着nusinersen 的商业化,许多未在三级保健中心定期随访或未登记在任何疾病登记处的成年脊髓性肌萎缩症(SMA)患者有了新的就诊机会。

方法

我们比较了定期随访患者和新就诊患者的人口统计学和疾病特征,包括运动和呼吸功能评估,并根据 SMA 类型对新就诊患者进行了细分。

结果

该队列包括 166 名成年患者(平均年龄:37.09 岁):1 型 1 例,2 型 65 例,3 型 99 例,4 型 1 例。其中 166 例为新就诊患者。新就诊患者与定期随访患者在年龄和疾病持续时间方面无显著差异。在整个队列以及 2 型和 3 型患者中,定期随访患者的 Hammersmith 功能运动量表扩展和修订上肢模块评分均高于新就诊患者。两组患者的通气状态(p = 0.013)和 Cobb 角 >50°(p = 0.039)也存在差异。两组患者脊柱侧弯手术发生率无差异(p > 0.05)。

结论

我们的结果显示了两个亚组之间的差异,尽管在 3 型患者中差异较小。在 2 型患者中,更严重疾病谱的新就诊患者比例更高。在新就诊患者中,只有约三分之一开始接受治疗,而定期随访患者中这一比例为 51%。确定未登记在疾病登记处的患者有助于重新定义 SMA 的总体患病率和不同表型的发生。

相似文献

1
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen.有时他们会回来:新型和旧型脊髓性肌萎缩症成人在 nusinersen 时代。
Eur J Neurol. 2021 Feb;28(2):602-608. doi: 10.1111/ene.14567. Epub 2020 Oct 31.
2
Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.5q 型脊髓性肌萎缩症成年患者使用 nusinersen 的安全性和治疗效果:一项前瞻性观察研究。
J Neuromuscul Dis. 2019;6(4):453-465. doi: 10.3233/JND-190416.
3
Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.在中国西部,接受 nusinersen 负荷期治疗后的脊髓性肌萎缩症患儿的运动功能和营养状况评估:一项回顾性研究。
BMC Neurol. 2023 Jan 23;23(1):35. doi: 10.1186/s12883-023-03063-3.
4
Nusinersen for adults with spinal muscular atrophy.注射用依洛硫酸酯酶纳治疗成人脊髓性肌萎缩症
Neurol Sci. 2023 Jul;44(7):2393-2400. doi: 10.1007/s10072-023-06698-9. Epub 2023 Mar 1.
5
Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.长期依库珠单抗治疗广泛范围脊髓性肌萎缩症严重度:真实世界经验。
Orphanet J Rare Dis. 2023 Aug 4;18(1):230. doi: 10.1186/s13023-023-02769-4.
6
The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.尼森仑赛治疗对脊髓性肌萎缩症患儿呼吸状况的影响。
Pediatr Int. 2022 Jan;64(1):e15310. doi: 10.1111/ped.15310.
7
Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.5q 型脊髓性肌萎缩症成年患者应用 nusinersen:一项多中心观察队列研究。
Eur J Neurol. 2022 Nov;29(11):3337-3346. doi: 10.1111/ene.15501. Epub 2022 Jul 24.
8
Drug treatment for spinal muscular atrophy types II and III.脊髓性肌萎缩症II型和III型的药物治疗。
Cochrane Database Syst Rev. 2020 Jan 6;1(1):CD006282. doi: 10.1002/14651858.CD006282.pub5.
9
Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.123 例 SMA 1 型或 2 型患儿治疗 1 年后接受 nusinersen 的疗效:一项法国真实世界观察性研究。
Orphanet J Rare Dis. 2020 Jun 12;15(1):148. doi: 10.1186/s13023-020-01414-8.
10
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen.接受 nusinersen 治疗的 II 型脊髓性肌萎缩症儿科患者的年龄相关治疗效果。
Neuromuscul Disord. 2021 Jul;31(7):596-602. doi: 10.1016/j.nmd.2021.03.012. Epub 2021 Apr 2.

引用本文的文献

1
Oral function tests in spinal muscular atrophy: closing the diagnostic gap in severely affected adult patients : A prospective observational study.脊髓性肌萎缩症的口腔功能测试:弥合重度成年患者的诊断差距:一项前瞻性观察性研究
J Orofac Orthop. 2025 Jun 24. doi: 10.1007/s00056-025-00597-8.
2
A Systematic Literature Review of the Natural History of Respiratory, Swallowing, Feeding, and Speech Functions in Spinal Muscular Atrophy (SMA).脊髓性肌萎缩症(SMA)呼吸、吞咽、喂养和言语功能自然史的系统文献回顾。
J Neuromuscul Dis. 2024;11(5):889-904. doi: 10.3233/JND-230248.
3
Design and Validation of a Clinical Outcome Measure for Adolescents and Adult Patients with Spinal Muscular Atrophy: SMA Life Study Protocol.
青少年和成年脊髓性肌萎缩症患者临床结局指标的设计与验证:脊髓性肌萎缩症生活研究方案
Neurol Ther. 2024 Feb;13(1):233-249. doi: 10.1007/s40120-023-00571-9. Epub 2024 Jan 5.
4
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment.脊髓性肌萎缩症:诊断和治疗的过去、现在和未来。
Int J Mol Sci. 2023 Jul 26;24(15):11939. doi: 10.3390/ijms241511939.
5
New therapies for spinal muscular atrophy: where we stand and what is next.脊髓性肌萎缩症的新疗法:现状及未来展望。
Eur J Pediatr. 2023 Jul;182(7):2935-2942. doi: 10.1007/s00431-023-04883-8. Epub 2023 Apr 17.
6
Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany.SMA 医疗护理的改进领域:来自德国全国患者登记处的证据。
Orphanet J Rare Dis. 2023 Feb 21;18(1):32. doi: 10.1186/s13023-023-02639-z.
7
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey.疾病修正疗法时代脊髓性肌萎缩症的流行率:意大利全国性调查。
Neurology. 2023 Mar 14;100(11):522-528. doi: 10.1212/WNL.0000000000201654. Epub 2022 Dec 2.
8
Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era.改善 SMA 患者的护理并赋予其力量:新治疗时代的行动呼吁。
J Neuromuscul Dis. 2021;8(4):543-551. doi: 10.3233/JND-200611.